NPS Pharma

NPS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing orphan products for patients with rare gastrointestinal and endocrine disorders, who have high unmet medical needs. The company's leading clinical programs involve two proprietary therapeutic peptide biologics: Gattex (the planned brand name for teduglutide) and Natpara (the planned brand name for parathyroid hormone 1-84, formerly known as NPSP558).